Edesa Biotech Inc.

Edesa Biotech advances #vitiligo clinical development program, selects JSS Medical Research as CRO for planned Phase 2 study. globenewswire.com/news-release/2… $EDSA #dermatology #AAD2026

Additional clinical data from Edesa’s #Phase3 study affirmed statistically significant mortality reductions in the full population of 278 patients. Exploratory analysis also demonstrated reduced mortality in #AKI, #sepsis and #pneumonia. globenewswire.com/news-release/2…

Edesa Biotech today reported #financialresults for fiscal 1Q 2026 $EDSA #vitiligo #ARDS globenewswire.com/news-release/2…

Edesa Biotech today reported #financialresults for fiscal year 2025 $EDSA globenewswire.com/news-release/2…

Edesa’s #Phase3 study of paridiprubart in patients with #ARDS met its primary and secondary endpoints, showing demonstrating a statistically significant and clinically meaningful benefit for reduced mortality at 28 days. $EDSA #biotech #drugdevelopment nasdaq.com/press-release/…

Edesa to participate in the @HCWCO 27th Annual Global Investment Conference next week in New York #HCWConference #vitiligo #ARDS $EDSA

Edesa Biotech today reported #financialresults for fiscal 3Q 2025 $EDSA globenewswire.com/news-release/2…

Edesa Biotech is a proud sponsor and supporter of World #Vitiligo Day and this year’s theme “Innovation for Every Skin” #WVD2025 #biotechnology #CXCL10 $EDSA worldvitiligoday.ca

Edesa Biotech today reported #financialresults for fiscal 2Q 2025 $EDSA globenewswire.com/news-release/2…

Edesa to join the annual Bloom Burton Healthcare Investor #Conference next week. $EDSA #vitiligo #BBHIC2025 globenewswire.com/news-release/2…

Edesa is pleased to announce that Peter Weiler will assume the role of CFO on May 1. Peter is a veteran of the #pharma and #biotech sectors, with extensive experience in finance and corporate strategy. globenewswire.com/news-release/2…

Congratulations to the Global #Vitiligo Foundation for hosting a great scientific symposium this week at #AAD2025. Edesa is proud to provide support for advancing research, education and collaboration within the vitiligo community.

Edesa Biotech today reported #financialresultsfor fiscal 1Q 2025 #vitiligo #ACD #ARDS #fibrosis $EDSA globenewswire.com/news-release/2…

Edesa Biotech Announces $15m private placement led by Velan Capital with participation from new and existing healthcare-focused institutional investors and insiders. globenewswire.com/news-release/2…

Edesa Biotech today reported #financialresults for FY 2024 #vitiligo #ACD #ARDS #fibrosis $EDSA globenewswire.com/news-release/2…

$EDSA announced today that the company’s CEO & Founder, Dr. Par Nijhawan, will invest up to $5 million in Edesa, including an immediate investment of ~$1.5 million. >> globenewswire.com/news-release/2… #vitiligo #ACD #ARDS #fibrosis #biotech

Edesa Biotech will be participating in #BIOEurope next week, Nov 4-6. Reach out to our team ahead of the event in the partnering system or at edesabiotech.com/about/contact-… #vitiligo #fibrosis #ARDS #dermatitis

Edesa Biotech today reported #financialresults for the 3rd quarter of FY 2024 #vitiligo #dermatitis #ARDS #fibrosis $EDSA globenewswire.com/news-release/2…

Par Nijhawan, CEO of Edesa Biotech, shares his thoughts on the recent BARDA announcement and what this means for the Company moving forward. $EDSA

We’ve selected host-directed therapeutics from @EdesaBiotech and InflaRx for inclusion in a phase 2 platform clinical trial to address acute respiratory distress syndrome (#ARDS). Learn more: ow.ly/FfIx50SnBA5